Skip to main content

Table 1 Tumor characteristics and pelvic treatment summary for 12 patients with gynecologic tumors who received a CRT boost

From: Dosimetric comparison of intensity-modulated, conformal, and four-field pelvic radiotherapy boost plans for gynecologic cancer: a retrospective planning study

Patient Primary Site FIGO Stage Pelvic Technique Posterior Pelvic Attenuator 1 PA RT Pelvic Dose 2 Concurrent Chemotherapy 3
1 Vagina 3 POP N Y 50 N
2 Vagina 1 4FB N N 50 Y
3 Cervix 2B 4FB Y N 50 Y
4 Cervix 3B POP N N 50 Y
5 Cervix 2B 4FB N N 45 Y
6 Cervix 2B 4FB Y N 50 Y
7 Cervix 1B 4FB Y N 45 N
8 Cervix 2B 4FB Y N 45 Y
9 Cervix 4A 4FB N N 45 N
10 Uterus 3A 4FB N N 45 Y
11 Uterus Recurrent 4FB N N 45 N
12 Cervix 2B 4FB N N 45 Y
  1. (1) 2 half-value posterior midline attenuator, 3 cm wide at mid-plane
  2. (2) Delivered in 25 fractions over 5 weeks
  3. (3) Cisplatinum 40 mg/m2 weekly for 5 weeks
  4. (FIGO) International Federation of Gynecology and Obstetrics
  5. (PA RT) Para-aortic radiotherapy
  6. (POP) Parallel opposed anterior and posterior fields
  7. (4FB) Four-field box technique